CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease

被引:42
作者
Haense, C. [1 ]
Buerger, K. [2 ,3 ,4 ]
Kalbe, E. [5 ]
Drzezga, A. [6 ]
Teipel, S. J. [2 ,3 ,4 ,7 ]
Markiewicz, P. [8 ]
Herholz, K. [5 ,8 ]
Heiss, W. D. [1 ]
Hampel, H. [2 ,3 ,4 ,9 ,10 ]
机构
[1] Max Planck Inst Neurol Res, D-50931 Cologne, Germany
[2] Univ Munich, Dept Psychiat, Dementia Res Sect, D-8000 Munich, Germany
[3] Univ Munich, Memory Clin, Alzheimer Mem Ctr, D-8000 Munich, Germany
[4] Univ Munich, Geriatr Psychiat Branch, D-8000 Munich, Germany
[5] Univ Cologne, Dept Neurol, Cologne, Germany
[6] Tech Univ Munich, Dept Nucl Med, Munich, Germany
[7] Univ Rostock, Dept Psychiat, Rostock, Germany
[8] Univ Manchester, Wolfson Mol Imaging Ctr, Manchester, Lancs, England
[9] AMiNCH, Discipline Psychiat, Sch Med, Dublin, Ireland
[10] AMiNCH, Univ Dublin Trinity Coll, TCIN, Trinity Ctr Hlth Sci, Dublin, Ireland
关键词
18F-FDG-PET; CSF phosphorylated tau; CSF total-tau; dementia severity; glucose metabolism;
D O I
10.1111/j.1468-1331.2008.02274.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purpose: We investigated associations between severity of cognitive impairment, cerebrospinal fluid (CSF) concentrations of total-tau (t-tau) protein and tau phosphorylated at threonin 181 (p-tau(181)) and regional glucose metabolism measured with 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET) in patients with probable Alzheimer's disease (AD). Methods: In 38 patients (mean age 66.5 +/- 8.0 years) with AD, Mini-Mental State Examination (MMSE) scores were evaluated and CSF levels of t-tau and p-tau(181) measured. All patients underwent an 18F-FDG-PET scan. Image analysis including correlation analysis and principal component analysis (PCA) were performed using SPM5 and VINCI. Results: Dementia severity (MMSE 21.2 +/- 4.9) correlated well with metabolic impairment especially in left hemisphere association areas that are typically affected in patients with AD (e.g. inferior parietal lobule, r = 0.512; medial temporal gyrus, r = 0.478; inferior temporal gyrus, r = 0.488; precuneus, r = 0.468; PCA: r = 0.639, F = 7.751; all P < 0.001). There were no associations between t-tau and p-tau(181) with dementia severity and only weak correlations between t-tau and cerebral glucose metabolism (superior parietal gyrus, r = -0.325, P < 0.05; precentral gyrus r = -0.418, P < 0.01; amygdala r = -0.362, P < 0.05). No correlations were found between p-tau(181) and regional hypometabolism in FDG-PET. Conclusion: MMSE and CSF t-tau represent different aspects of disease severity. Whilst MMSE is closely related to impaired cerebral glucose metabolism, CSF t-tau is less closely related and appears to be less well suited for assessment of disease progression.
引用
收藏
页码:1155 / 1162
页数:8
相关论文
共 53 条
[11]   The neural substrates of episodic memory impairment in Alzheimer's disease as revealed by FDG-PET:: relationship to degree of deterioration [J].
Desgranges, B ;
Baron, JC ;
Lalevée, C ;
Giffard, B ;
Viader, F ;
de la Sayette, V ;
Eustache, F .
BRAIN, 2002, 125 :1116-1124
[12]   The neural substrates of memory systems impairment in Alzheimer's disease -: A PET study of resting brain glucose utilization [J].
Desgranges, B ;
Baron, JC ;
de la Sayette, V ;
Petit-Taboué, MC ;
Benali, K ;
Landeau, B ;
Lechevalier, B ;
Eustache, F .
BRAIN, 1998, 121 :611-631
[13]   Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment [J].
Fellgiebel, A ;
Siessmeier, T ;
Scheurich, A ;
Winterer, G ;
Bartenstein, P ;
Schmidt, LG ;
Müller, MJ .
BIOLOGICAL PSYCHIATRY, 2004, 56 (04) :279-283
[14]  
Fleischmann, 1995, NURNBERGER ALTERS IN
[15]   MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN [J].
FOLSTEIN, MF ;
FOLSTEIN, SE ;
MCHUGH, PR .
JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) :189-198
[16]   Biological markers for therapeutic trials in Alzheimer's disease - Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease [J].
Frank, RA ;
Galasko, D ;
Hampel, H ;
Hardy, J ;
de Leon, MJ ;
Mehta, PD ;
Rogers, J ;
Siemers, E ;
Trojanowski, JQ .
NEUROBIOLOGY OF AGING, 2003, 24 (04) :521-536
[17]  
Geldmacher DS, 2006, J NUTR HEALTH AGING, V10, P417
[18]   Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease -: A comparative cerebrospinal fluid study [J].
Hampel, H ;
Buerger, K ;
Zinkowski, R ;
Teipel, SJ ;
Goernitz, A ;
Andreasen, N ;
Sjoegren, M ;
DeBernardis, J ;
Kerkman, D ;
Ishiguro, K ;
Ohno, H ;
Vanmechelen, E ;
Vanderstichele, H ;
McCulloch, C ;
Möller, HJ ;
Davies, P ;
Blennow, K .
ARCHIVES OF GENERAL PSYCHIATRY, 2004, 61 (01) :95-102
[19]   Value of CSF β-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment [J].
Hampel, H ;
Teipel, SJ ;
Fuchsberger, T ;
Andreasen, N ;
Wiltfang, J ;
Otto, M ;
Shen, Y ;
Dodel, R ;
Du, Y ;
Farlow, M ;
Möller, HJ ;
Blennow, K ;
Buerger, K .
MOLECULAR PSYCHIATRY, 2004, 9 (07) :705-710
[20]   Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study [J].
Hansson, O ;
Zetterberg, H ;
Buchhave, P ;
Londos, E ;
Blennow, K ;
Minthon, L .
LANCET NEUROLOGY, 2006, 5 (03) :228-234